国产午夜福利视频在线播放一区,伊人久久大香线蕉综合热线,国产一区二区波多野结衣,国产精品丝袜久久久久av,婷婷五月亚洲中文字开心,欧美日韩亚洲综合在线,色综合一区二区三区,国产黄色小视频91在线观看,成人片毛片AAA片免费,久久亚洲AV无码专区成人国产,国产1024香蕉在线观看

2005年畢業(yè)于東北林業(yè)大學(xué)，獲理學(xué)學(xué)士學(xué)位；2011年畢業(yè)于北京大學(xué)，獲理學(xué)博士學(xué)位。2011年8月至2016年7月先后在美國約翰霍普金斯大學(xué)和紀(jì)念斯隆凱特琳癌癥研究中心從事腫瘤生物學(xué)博士后研究；2016年8月受聘于中科院上海生化與細(xì)胞所，任研究員、研究組長、博士生導(dǎo)師。目前擔(dān)任中國細(xì)胞生物學(xué)學(xué)會類器官研究與應(yīng)用分會會長（2025年-今）、上海市細(xì)胞生物學(xué)學(xué)會副理事長（2025年-今）、中國遺傳學(xué)會類器官分會副主任委員（2024年-今）、中國醫(yī)藥生物技術(shù)協(xié)會疾病模型專業(yè)委員會副主任委員（2021年-今）、Cell Reports期刊編委等學(xué)術(shù)任職。獲得尚思探索學(xué)者（2024年）、國家杰出青年科學(xué)基金（2021年）、上海市優(yōu)秀學(xué)術(shù)帶頭人（2021年）、國家高層次人才青年項目（2016年）等項目支持。曾獲談家楨生命科學(xué)創(chuàng)新獎（2025年）、中國科學(xué)院優(yōu)秀導(dǎo)師（2025）、樹蘭醫(yī)學(xué)青年獎（2024年）、上海市科技系統(tǒng)青年五四獎?wù)拢▓F體，負(fù)責(zé)人）（2021年）等榮譽。

我們以組織生理病理類器官模型、小鼠模型和臨床腫瘤標(biāo)本的整合分析為基礎(chǔ)，運用類器官培養(yǎng)技術(shù)、單細(xì)胞多組學(xué)測序技術(shù)、空間多組學(xué)測序技術(shù)、細(xì)胞譜系示蹤技術(shù)等分子細(xì)胞生物學(xué)技術(shù)手段，整合生物信息學(xué)分析方法，研究成體干細(xì)胞和腫瘤細(xì)胞命運可塑性的分子調(diào)控網(wǎng)絡(luò)和治療抵抗機理，篩選抗腫瘤新靶點，開發(fā)新型抗癌藥物，合作開展相關(guān)臨床試驗，延長腫瘤患者的生存。目前的主要研究內(nèi)容包括：

1)研究成體干細(xì)胞和腫瘤祖細(xì)胞，尋找維持成體干細(xì)胞多能性的主要調(diào)控基因，并基于此建立并優(yōu)化類器官培養(yǎng)技術(shù)體系；

2)體外重建不同時期的腫瘤類器官模型，研究腫瘤細(xì)胞可塑性與腫瘤抗藥性的分子機理；

3)建立來源于中國癌癥病人的類器官模型庫，進行高通量藥物篩選，探尋新的抗腫瘤藥物靶點，發(fā)展新型抗癌藥物，合作開展相關(guān)臨床試驗。

1. Wang H^#, Li YG^#,*, Li YK^#, Tang SJ^#, Zhang YH^#, Yin XY, He J, Zhu YQ, Zhang Y, Shi XH, Gao SZ, Li B, Zhu LY, Yuan S, Pan YQ, Shi ML, Li PH, Teng CQ, Zhong CL, Yang XL, Fu ZD, Liu XY, Kang XC, Kang YN, Zheng KL, Jing W, Xu XF, Guo SW, Chen LN*, Gao D*, Jin G*. Paired organoids reveal chemotherapy-induced vulnerabilities in pancreatic cancer. Cell Stem Cell. Cancer Letters. 2026 Jan 19;641:218252.
2. Li YG^#, Tang SJ^#, Wang H^#, Zhu HW^#, Lu YR^#, Zhang YH^#, Guo SW^#, He J, Li YK, Zhang Y, Shi XH, Miao YX, Zhong CL, Zhu YQ, Ju Y, Liu YJ, Sun MY, Wang Y*, Chen LN*, Zhou H*, Jin G*, Gao D*. A pancreatic cancer organoid biobank links multi-omics signatures to therapeutic response and clinical evaluation of statin combination therapy. Cell Stem Cell. 2025 Sep 4;32(9):1369-1389.e14.
3. Xu XF^#, Guo SW^#, Gu HH^#, Cha ZS^#, Shi XH, Yin XY, Wang H, Gao SZ, Li B, Zhu LY, Jing W, Zheng KL, Shao Z, Cheng P, Zheng CH, Shih YP, Li YG, Qian BH, Gao D*, Tran E*, Jin G*. Identification and validation of a T cell receptor targeting KRAS G12V in HLA-A*11:01 pancreatic cancer patients. JCI Insight. 2025 Jan 23;10(2):e181873.
4. Li F^#, Dai PF^#, Shi HL^#, Zhang YJ^#, He J, Gopalan A, Li D, Chen Y, Du YR, Xu GL, Yang WW*, Liang C*, Gao D*. LKB1 inactivation promotes epigenetic remodeling-induced lineage plasticity and antiandrogen resistance in prostate cancer. Cell Res. 2025 Jan 2. doi: 10.1038/s41422-024-01025-z.
5. Guo WX^#, Zhang XY^#, Li L^#, Shao PF^#, Liang C^#, Zhang HJ, Wang SM, Peng YY, Liu K, Luo J, Ju Y, DeMarzo AM*, Yu C*, Chen LN*, Zhou B*, Gao D*. JAK/STAT signaling maintains intermediate cell population in prostate basal cell fates determination. Nat Genet. 2024 Dec;56(12):2776-2789.
6. Huang PW^#, Gao WN^#, Fu CY^#, Wang M^#, Li YG^#, Chu BZ, He A, Li Y, Deng XM, Zhang YH, Kong Q, Yuan JX, Wang HB, Shi Y*, Gao D*, Qin RY*, Hunter T, Tian RJ*. Clinical functional proteomics of intercellular signalling in pancreatic cancer. Nature. 2024 Nov 13. doi: 10.1038/s41586-024-08225-y.
7. Lutolf MP, Radisic M, Beekman J, Huh DD, Huch M, Turco MY, Tahmasebi Birgani ZN, Gao D (Personalized Cancer Organoid Models), Yao R, Lin H, Takebe T. In vitro human cell-based models: What can they do and what are their limitations? Cell. 2024 Aug 22;187(17):4439-4443. (Invited perspectives for Cell’s 50th?anniversary)
8. Zhang XY^#, Wang J^#, Guo WX*, Zhang HJ, Zhou B, Chen Y, Gao D*. The cell fates of intermediate cell population in prostate development. Cell Insight. 2024 July; 100182.
9. Li F^#, Xing XD^#, Jin QQ^#, Wang XM^#, Dai PF^#, Han M^#, Shi HL, Zhang Z, Shao XL, Peng YY, Zhu YQ, Xu JY, Li D, Chen Y, Wu W, Wang Q, Yu C*, Chen LN*, Bai F*, Gao D*. Sex differences orchestrated by androgens at single-cell resolution. Nature. 2024 May;629(8010):193-200.
10. Zhu YJ^#, Tang SJ^#, Yuan QY^#, Fu J^#, He J^#, Liu Z, Zhao XF, Li YG, Zhao Y, Zhang YN, Zhang XY, Zhang YQ, Zhu YQ, Wang WW, Zheng B, Wu R, Wu T, Yang S, Qiu XY, Shen SY, Hu J, Chen LN*, Wang Y, Wang HY*, Gao D*, Chen L*. Integrated characterization of hepatobiliary tumor organoids provides potential landscape of pharmacogenomic interactions. Cell Rep Med. 2024 Jan 17:101375.
11. Li YG^#, Tang SJ^#, Shi XH^#, Lv JW^#, Wu XY^#, Zhang YH^#, Wang H, He J, Zhu YQ, Ju Y, Guo SW, Yang WW*, Yin HY*, Chen LN*, Gao D*, Jin G*. Metabolic classification suggests the GLUT1/ALDOB/G6PD axis as a therapeutic target in chemotherapy-resistant pancreatic cancer. Cell Rep Med. 2023 Sep 19;4(9):101162.
12. Li X^#, Li F^#, Ye F^#, Guo HT, Chen WT, Jin J, Wang YR, Dai PF, Shi HL, Tao HR, Dang WZ, Ding YL, Wang MC, Jiang HL, Chen KX, Zhang NX, Gao D*, Zhang YY*, Luo C*. Spermine is a natural suppressor of AR signaling in castration-resistant prostate cancer. Cell Rep. 2023 Jul 14;42(7):112798.
13. Gao D. Cell fate determination and lineage plasticity in prostate cancer. Asian J Androl. 2023 Mar;25(2):149-151.
14. Li L^#, Xu YL^#, Yan LL^#, Li X, Li F, Liu Z, Zhang CC, Yuan L*, Gao D*, Cheng X*, Chen LN*.? Dynamic network biomarker factors orchestrate cell-fate determination at tipping points during hESC differentiation. Innovation (Camb). 2022 Dec 20;4(1):100364.
15. He J^#, Cui HY^#, Shi XH, Jin QQ, Han XM, Han TT, Peng JY, Guo SW, Zhao Y, Zhou B, Chen LN, Chen L, Zeng YA, Wang HY*, Jin G*, Gao D*. Functional hepatobiliary organoids recapitulate liver development and reveal essential drivers of hepatobiliary cell fate determination. Life Medicine. 2022 Dec 07; lnac055.
16. Han M^#, Li F^#,*, Zhang YH^#, Dai PF, He J, Li YG, Zhu YQ, Zheng JK, Huang H, Bai F, Gao D*. FOXA2 drives lineage plasticity and Kit pathway activation in neuroendocrine prostate cancer. Cancer Cell. 2022 Nov 14;40(11):1306-1323.e8.
17. Peng JY^#, Li F^#, Wang J, Wang CX, Jiang YA, He J, Yuan K, Bei JX, Wang V, Zhou B, Chen LN, Gao D*, Zhao Y*. Identification of a rare Gli1⁺ progenitor cell population contributing to liver regeneration during chronic injury. Cell Discovery. 2022 Nov 1;8(1):118.
18. Wang WW^#,? Ma LL^#, Zheng X^#, Yuan TG, Bao JX, Zhu YJ, Zhao XF, Zhao Y, Zong YL, Zhang YN, Shen SY, Qiu XY, Yang S, Wang HY*, Gao D*, Wang P*, Chen L*. Tumor specific circRNA-derived neoantigen peptide identification for hepatobiliary tumor. Engineering. 2022 DOI: 10.1016/j.eng.2022.06.008
19. Wang YQ, Zhang LP, Liu Y, Tang LL, He J, Sun XQ, Younis MH, Cui DX, Xiao HH, Gao D*, Kong XY*, Cai WB*, Song J*. Engineering CpG-ASO-Pt-loaded Macrophages (CAP@M) For Synergistic Chemo-/Gene-/Immuno-Therapy. Adv Healthc Mater. 2022 Aug;11(15):e2201178.
20. Wang WW^#, Yuan TG^#,? Ma LL^#, Zhu YJ^#, Bao JX, Zhao XF, Zhao Y, Zong YL, Zhang YN, Yang S, Qiu XY, Shen SY, Wu R, Wu T, Wang HY*, Gao D*, Wang P*, Chen L*. Hepatobiliary tumor organoids reveal HLA I neoantigen landscape and antitumoral activity of neoantigen peptide enhanced with ICIs. Adv Sci (Weinh). 2022 Aug;9(22):e2105810.
21. Shi XH^#, Li YG^#, Yuan QY^#, Tang SJ^#, Guo SW^#, Zhang YH, He J, Zhang XY, Han M, Liu Z, Zhu YQ, Gao SZ, Wang H, Xu XF, Zheng KL, Jing W, Chen LN*, Wang Y*, Jin G*, Gao D*. Integrated profiling of human pancreatic cancer organoids reveals chromatin accessibility features associated with drug sensitivity. Nat Commun. 2022 Apr 21;13(1):2169.
22. Gu YQ^#, Cao J^#, Zhang XY^#, Gao H^#, Wang YY^#, Wang J^#, He J^#, Jiang XY^#, Zhang JL, Shen GH, Yang J, Zheng XC, Hu GW, Zhu YF, Du SJ, Zhu YK, Zhang R, Xu JQ, Zhang CC, Lan F, Qu D, Xu GL, Zhao Y*, Gao D*, Xie YH*, Luo M*, Lu ZG*. Receptome profiling identifies KREMEN1 and ASGR1 as alternative functional receptors of SARS-CoV-2. Cell Res. 2022 Jan;32(1):24-37.
23. Fu X^#, He Q^#, Tao Y^#, Wang DM^#, Wang W^#, Wang YL^#, Yu QC^#, Zhang F^#, Zhang XY^#, Chen YG*, Gao D*, Hu P*, Hui LJ*, Wang XQ*, Zeng YA*. Recent advances in tissue stem cells. Sci China Life Sci. 2021 Dec;64(12):1998-2029.
24. Zhao Y^#, Li ZX^#, Zhu YJ^#, Fu J^#, Zhao XF, Zhang YN, Wang S, Wu JM, Wang KT, Wu R, Sui CJ, Shen SY, Wu X, Wang HY*, Gao D*, Chen L*. Single cell transcriptome analysis uncovers intra-tumoral heterogeneity and underlying mechanisms for drug resistance in hepatobiliary tumor organoids. Adv Sci (Weinh). 2021 Jun;8(11):e2003897.
25. Li F^#, Han M^#, Dai PF^#, Xu W^#, He J^#, Tao XT^#, Wu Y^#, Tong XY, Xia XY, Guo WX, Zhou YJ, Li YG, Zhu YQ, Zhang XY, Liu Z, Aji R, Cai X, Li YT, Qu D, Chen Y, Jiang SB, Wang Q, Ji HB, Xie YH*, Sun YH*, Lu L*, Gao D*. Distinct mechanisms for TMPRSS2 expression explain organ-specific inhibition of SARS-CoV-2 infection by enzalutamide. Nat Commun. 2021 Feb 8;12(1):866.
26. Li F^#, Yuan QY^#, Di W^#, Xia XY^#, Liu Z, Mao NH, Li L, Li CF, He J, Li YG, Guo WX, Zhang XY, Zhu YQ, Aji R, Wang SQ, Chi P, Carver B, Wang Y*, Chen Y*, Gao D*. ERG orchestrates chromatin interactions to drive prostate cell fate reprogramming. J Clin Invest. 2020 Nov 2;130(11):5924-5941.
27. Guo WX^#, Li L^#, He J, Liu Z, Han M, Li F, Xia XY, Zhang XY, Zhu Y, Wei Y, Li YG, Aji R, Dai H, Wei H, Li CF, Chen Y*, Chen LN*, Gao D*. Single-cell transcriptomics identifies a distinct luminal progenitor cell type in distal prostate invagination tips. ?Nat Genet. 2020 Sep;52(9):908-918.
28. He J, Zhang X, Xia XY, Han M, Li F, Li CF, Li YG, Gao D*. Organoid technology for tissue engineering. J Mol Cell Biol. 2020 Aug 1;12(8):569-579. (Invited review)
29. Tang J^#, Wang HX^#, Huang XZ^#, Li F^#, Zhu H, Li Y, He LJ, Zhang H, Pu WJ, Liu K, Zhao H, Bentzon JF, Yu Y, Ji Y, Nie Y, Zhang L*, Gao D*, Zhou B*. Sca1⁺ Vascular Stem Cells Contribute to Smooth Muscle for Artery Repair and Regeneration. Cell Stem Cell. 2020 Jan 2;26(1):81-96.
30. Xia XY, Li F, He J, Aji R, Gao D*. Organoid technology in cancer precision medicine. Cancer Lett. 2019 Aug 10;457:20-27. (Invited review)
31. Ding YF^#, Li N^#, Dong BJ^#, Guo WX, Wei H, Chen QL, Yuan HR, Han Y, Chang HW, Kan S, Wang XG, Pan Q, Wu P, Peng C, Qiu T, Li QT, Gao D*, Xue W*, Qin J*. Chromatin remodeling ATPase BRG1 and PTEN are synthetic lethal in prostate cancer. J Clin Invest. 2019 Feb 1;129(2):759-773.
32. Gao D^#, Vela I^#, Sboner A^#, Iaquinta PJ^#, Karthaus WL, Gopalan A, Wanjala JN, Dowling C, Undvall EA, Wongvipat J, Kossai M, Barboza LP, Di W, Cao Z, Zhang QF, Sirota I, Ran Ll, Solomon SB, MacDonald TY, Beltran H, Mosquera J,? Eastham JA, Touijer KA, Scardino PT, Laudone VP, Rathkopf DE, Morris MJ, Danila DC, Slovin SF, Chi P, Clevers H, Carver B, Rubin MA, Scher HI, Sawyers CL*, Chen Y*. Generation of in vitro organoids cultures derived from patients with advanced prostate cancer. Cell. 2014 Sep; 159(1): 176-187.

合影